Jyong Biotech Ltd(MENS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:58 PM ET (Korea 9/12 05:58)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.06 | Insider Own | 62.2% | Shs Outstand | 74.2M | Perf Week | -12.33% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 28.1M | Perf Month | -2.45% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | - | Inst Own | 0.69% | Short Float | 0.68% | Perf Quarter | 16.72% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 3.8% | Short Ratio | 2.35 | Perf Half Y | -7.44% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -34.42% | Short Interest | 0.19M | Perf YTD | -49.62% |
| Book/sh | -0.34 | P/C | 125.19 | EPS past 3/5Y | 11.59% -2.18% | ROE | - | 52W High | -97.03% ($67.00) | Perf Year | -96.91% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 39.16% ($1.43) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -56.02% | Gross Margin | - | Volatility(W/M) | 11.08% 8.01% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.45 | EPS Q/Q | -102.19% | Profit Margin | - | RSI (14) | 40.08 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.45 | Sales Q/Q | - | SMA20 | -8.55% ($2.18) | Beta | 2.43 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -10.01% ($2.21) | Rel Volume | 0.56 | Prev Close | $2.01 |
| Employees | 27 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -54.37% ($4.36) | Avg Volume(3M) | 0.08M | Price | $1.99 |
| IPO | 2025/6/17 | Option/Short | Yes/Yes | Trades | 922 | Volume | 45,306 | Change | -1% |
Company
MENS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Ginkgo BioTech (MENS) is a plant-derived drug development company headquartered in New Taipei City, Taiwan. It focuses on developing therapeutics for urological diseases and is advancing clinical-stage candidates targeting benign prostatic hyperplasia (BPH), prostate cancer, and interstitial cystitis. The company is pursuing clinical development alongside a regulatory approval strategy aimed at the U.S., European Union, and Asian markets.
Over the past 1 year, on the lower side
97% below its 1-year high.
MENS has weak earning power
Review management risk carefully before investing
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BIB 0.00%
IBBQ 0.00%
IBB 0.00%
ONEQ 0.00%It ranks #4 in the industry
Based on market cap of $148M.
MENS $148M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is MENS?
MENS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MENS?
The market cap of MENS is approximately $148M, ranking 4,310 within its sector.
What is the 52-week high and low for MENS?
MENS has recorded a 52-week high of $67.00 and a low of $1.43.
